International Research Journal of Education and Technology

Peer Reviewed Journal

ISSN 2581-7795

REVIEW ON INFERTILITY IN WOMEN

Dhaktode Suraj and Akshay Kulthe

ABSTRACT

The difficulty to conceive or subfertility constitutes a major social and psychological burden amongst couples especially in African women. In Nigeria, it is estimated that female factors and unexplained infertility generally accounts for 50-80% of cases of infertility and thus the need to review the various works done by researchers. In this review the contributions of the different etiological factors in female infertility was looked into and attempt was made to update the available information on the management of female infertility. The main aim of this review is to generate information which could act as guideline in the evaluation of female infertility. From the reviewed studies on female infertility it is concluded that a loss of 5-10 % of body weight in obese anovulatory infertile women, maintenance of a healthy lifestyle, prevention and prompt treatment of sexually transmitted diseases and not delaying parenthood are amongst the purported good preventive measures to tackle infertility amongst infertile women.

Key words: Female infertility, hypothyroidism, anovulation, hyperprolactinemia,

INTRODUCTION

Infertility is the inability of a couple to achieve pregnancy over an average period of one year (in a woman under 35 years of age) or 6 months (in a woman above 35 years of age) despite adequate, regular (3-4 times per week), unprotected sexual intercourse [13]. Infertility may also be referred to as the inability to carry a pregnancy to the delivery of a live baby. Infertility can be due to the woman, the man, or both; primary or secondary. In primary infertility, the couples have never been able to conceive; while in secondary infertility there is difficulty in conceiving after having conceived (either carried the pregnancy to term or had a miscarriage). Secondary infertility is not present if there has been a change of partners within theculiar chances to be infertile.

Cervical infertility (CI)
involves inability of spermatozoa to get to the uterus due to damage to the cervix or cervical factors such as cervical stenosis [53]; antispeerm antibodies [18];

inadequate, hostile or non-receptive cervical mucus [17], and cervical infections from sexually transmitted diseases Chlamyd

Epidemiology

Infertility is a complex disorder with significant medical, psychosocial, and economic problems [57]. Data from population - based studies suggest that 10-15 % of couples in the world experience infertility [16]. In Africa, its prevalence is particularly high in sub-Sahara ranging from 20% to 60% of couples [43]. It is estimated that female factors and unexplained infertility accounts for 50-80% while the male factor accounts for 20-50% of the cause of infertility in different parts of Nigeria [15].

Available evidence suggests that the social consequences of infertility are particularly profound for African women as compared to men [28]. Community based data suggest that up to 30 per cent of couples in some parts of Nigeria may have proven difficulties in achieving a desired conception after two years of marriage without the use of contraceptives [2].

RISK FACTORS AND CAUSES

Infertility may be caused by an underlying medical condition that may damage the fallopian tubes, interferes with ovulation, or causes hormonal complications. These medical conditions include pelvic inflammatory disease, endometriosis, polycystic ovarian syndrome, premature ovarian failure, uterine fibroids and environmental factors. Other causes of infertility in females include ovulation problems, tubal blockage, age-related factors, uterine problems, previous tubal ligation and hormone imbalance while the main cause of male infertility is poor semen quality.

Environmental factors and infertility

The etiological importance of environmental factors in infertility has been stressed [26].Toxins such as glues, volatile organic solvents or silicones, physical agents, chemical dusts, and pesticides are implicated in infertility
[35]. Other potentially harmful occupational environmental exposures such as chlorinated hydrocarbons and fumicides have also been discovered to be associated with the increased link of spontaneous miscarriage in women [26]. Hence

individuals having direct contact with or exposure to such chemicals have high chances of having primary or secondary infertility as the case may be. Estrogen-like hormone-disrupting chemicals such as phthalates are of particular concern for effects on babies of women.

Weight changes and infertility

Ovarian dysfunction could be caused by weight loss and excessive weight gain with body mass index (BMI) greater than 27 kg / m 2 [27]. Excess weight has also been found to have effect on treatment efficacy and outcomes of assisted reproductive technique [19]. Estrogen is produced by the fat cells and primary sex organs [40] and thus, state of high body fat or obesity causes increase in estrogen production which the body interprets as birth control, limiting the chances of getting pregnant [5]. Also, too little body fat causes insufficient estrogen production and thus menstrual irregularities with anovulatory cycle [5]. Proper nutrition in early life had been linked to be a major factor for later fertility [52].

Age and Infertility

Fertility declines with age. Female fertility is at its peak between the ages of 18 and 24 years [3], while, it begins to decline after age 27drops at a somewhat greater rate after age 35 [25]. In terms of ovarian reserve, a typical woman has 12% of her reserve at age 30 and has only 3% at age 40 [56]. 81% of variation in ovarian reserve is due to age alone [56], making age the most important factor in female infertility. Ovulatory dysfunction is more common in younger than old couples [37].

Life style and infertility

Fertility of an individual may be influenced by life style choice [24]. Tobacco smoking and alcohol intake contribute to infertility. Cigarette smoking interferes with folliculogenesis (nicotine and other harmful chemicals in cigarettes interfere with estrogen synthesis), embryo transport, endometrial receptivity, endometrial angiogenesis, uterine blood flow and the uterine myometrium [14]. Some damage is irreversible, but stopping smoking can prevent further damage [5]. Smokers are 60% more likely to be infertile than non-smokers. Smoking reduces the chances of IVF producing a live birth by 34% and increases the risk of an IVF pregnancy miscarrying by 30% [47]. Canabis smoking, such as marijuana causes disturbances in the endocannabinoid system, potentially causing infertility [29].

Alcohol intake, on the other hand, is associated with elevated oestrogen level [39] and this elevated oestrogen level reduces FSH secretions which then suppresses folliculogenesis and results in anovulation [34].

Hormonal Imbalance and Infertility

The hypothalamus, through the release of gonadotrophin releasing hormones, controls the pituitary gland which directly or indirectly controls most other hormonal glands in the human body. Thus, alterations in the chemical signals from the hypothalamus can affect the pituitary gland, ovaries, thyroid, mammary gland and hence, hormonal abnormalities. Hormonal anomalies that affect ovulation include hyperthyroidism, hypothyroidism, polycyctic ovary syndrome (also known as Stein-Leventhal syndrome) and hyperprolactinemia [31]. Hormonal imbalance is an important cause of anovulation. Women with hormonal imbalance will not produce enough follicles to ensure the development of an ovule. Changes in hormonal balance of the hypothalamo-pituitary-adrenal axis (HPA-axis) could be caused by stress [21].

Hyperprolactinemia and infertility

Hyperprolactinemia (HP) is the presence of abnormally-high prolactin levels in the blood. Values lesser than 580 mIU/L are considered normal for women. Prolactin is produced by the anterior pituitary gland and is primarily associated with breast development during pregnancy and induces lactation. However, prolactin also binds to specific receptors in the gonads, lymphoid cells, and liver [33].

Hyperprolactinaemia may occur primarily as a result of normal physiological changes during pregnancy, breastfeeding, mental stress, hypothyroidism, or sleep. Pathologically, it may be due to diseases affecting the hypothalamus and pituitary gland or secondary to disease of other organs such as the liver, kidneys, ovaries and thyroid. Also, it may be as a result of disruption of the normal body regulations of prolactin levels by drugs, medicinal herbs and heavy metals; [33].

Hyperprolactinemia causes infertility by increasing the release of dopamine from the hypothalamus which inhibit gonadotrophin- releasing hormone (GnRH) and thus gonadal steroidogenesis and eventual infertility.

Ovarian functional problem and infertility

Infertility resulting from ovarian dysfunction may be due to absence of eggs in the ovaries or due to a complete blockage of the ovaries. Ovarian dystrophy (physical damage to the ovaries, or ovaries with multiple cysts) and luteinized unruptured follicle syndrome (LUFS), in which case the egg may have matured properly but the follicle failed to burst or even burst without releasing the egg may occur and cause anovulatory cycle [7]. Polycystic ovaries syndrome (PCOS) is usually a hereditary problem and accounts for up to 90% of cases of anovulation [8]. In PCOS the ovaries produce high amounts of androgens, particularly testosterone and thus amenorrhea or oligomenorrhea is quite common.

The increased androgen production in PCO results in high levels of luteinizing hormone (LH) and low levels of follicle-stimulating hormone (FSH), so that follicles are prevented from producing a mature egg. The hyperandrogenism can cause obesity, facial hair, and acne, although not all women with PCOS have such symptoms. PCOS also poses a high risk for insulin resistance, which is associated with type 2 diabetes.

Tubal factors and infertility

Tubal (ectopic) and peritoneal factors of importance in infertility include endometriosis [54], pelvic adhesions, pelvic inflammatory diseases usually due to Chlamidia [23], tubal occlusion [20] and tubal dysfunction. Tubal factors have similar prevalence as peritoneal factors [37]. Endometriosis is a noncancerous condition and may cause adhesions between the uterus, ovaries, and fallopian tubes, thereby preventing the transfer of the egg to the tube and thus infertility.

Uterine factors and infertility

Notable amongst uterine factors are uterine malformation such as abnormal uterine shape and intrauterine septum [46]; polyps, leiomyoma, and Asherman's syndrome [32]. Benign fibroid in the uterus are extremely common in women in their 30s. Large fibroids may cause infertility by impairing the uterine lining, blocking the fallopian tube, distorting the shape of the uterine cavity or altering the position of the cervix.

Thyroid disease and infertility

Thyroid disease had been shown to be associated with increase risk of prematurity or stillbirth [6].The prevalence of hypothyroidism in women of reproductive age (20-40 years) varies between 2% to 4% [9]. In primary hypothyroidism the serum thyroxine (T4) level is low and there is decreased negative feedback on the hypothalamo-pituitary axis. The resulting increased secretion of thyrotropin releasing hormone (TRH) stimulates the thyrotrophs

and lactotrophs, thereby increasing the levels of both thyroid stimulating hormone (TSH) and prolactin [51] and thus
ovulatory dysfunction due to hyperprolactinemia. Prolactin production can also be stimulated by vasoactive
intestinal peptide (VIP), epidermal growth factor and dopamine receptor agonists.

Hyperthyroidism on the other hand is characterized by suppressed serum TSH and increased thyroxine (T4),
triiodothyronine (T3), or both. Hyperthyroidism in women of reproductive age is caused by Graves' disease, toxic
goiter and thyroiditis. In the work of Krassas et al a higher incidence of hyperthyroidism was associated with
irregular menstrual cycle ranging from hypomenorrhea, polymenorrhea, and oligomenorrhea, to hypermenorrhea
[30].

Sexually transmitted disease (STD) and infertility

STDs are diseases transmitted from either sex through sexual activity with an infected partner caused by viruses,
bacteria, or parasitic microorganisms. STDs are a leading cause of infertility. They are often asymptomatic but may
display few symptoms, with the risk of failing to seek proper treatment in time to prevent decreased fertility [5].
Some of the identified STDs (such as syphilis, trichomoniasis, chancroid, Chlamydia, gonorrhea, herpes simplex
virus, human papilloma virus, HIV, lymphogranuloma venerum) are treatable while many are not, with HIV virus
being the most serious sexually transmitted infection as it eventually leads to death. STDs can also be transmitted
vertically from mothers to children during pregnancy and childbirth.

Pelvic inflammatory disease (PID) and infertility
Pelvic inflammatory disease (PID) comprises of a variety of infections affecting the pelvic organs caused by
different microorganisms such as bacteria and inflammatory conditions of parts of the gastrointestinal tract that lies
in the pelvic area such as salpingitis from septic abortion or ascending infection. PID may be caused by sexually

transmitted diseases from Chlamydia trachomatis and Gonorrhea and can eventually result into abscess formation,
adhesions, scarring, tubal blockade, tubal damage, ectopic pregnancy and thus infertility. Mumps had also been
reported to cause spontaneous abortion in about 27% of cases during the first trimester of pregnancy [50].

Structural obstruction and infertility
Congenital abnormalities that affect the genital tract may cause infertility. In Mullerian agenesis the vagina or the
uterus fail to develop and thus infertility. Also, following pelvic surgery, postsurgical or postinfective uterine or
abdominal adhesions and scarrings may occasionally result and this could restrict the movement of ovaries and
fallopian tubes and cause infertility. Asherman syndrome as a result of repeated injuries to the uterine linings from
multiple dilatation and curettage of the uterus can cause obstructions and secondary amenorrhea.

Chemotherapy and infertility
Studies have shown that the antral follicle count decreases after the third series of chemotherapy, whereas follicle
stimulating hormone (FSH) reaches menopausal levels after the fourth series; inhibin B and anti Mullerian hormone
levels also decreases following chemotherapy [49]. Drugs with high risk of infertility include procarbazine,
cyclophosphamide, ifosfamide, busulfan, melphalan, chlorambucil and chlormethine ; drugs like doxorubicin,
cisplatin and carboplatin have medium risk while therapies with plant derivatives (such as vincristine and
vinblastine), antibiotics (such as bleomycin and dactinomycin) and antimetabolites (such as methotrexate,
mercaptopurine and 5-fluoruracil) have low risk of gonadotoxicity [10].

Diagnosis of infertility

In any infertility work-up both male and female partners are considered to be a major contributor and are so investigated especially if the woman is above 35 years of age or if either partner has known risk factors for infertility. Male

factors have to be removed before subjecting the female partner to any expensive but invasive test.

Medical History and Physical Examination

The first step in any infertility work up is a complete medical history and physical examination of both couple.
Generally, diagnosis of hyperprolactinemia is discovered from the history of oligomenorrhea, amenorrhea, or
galactorrhea. Lifestyle issues such as ciggarrete smoking, canabis, drug and alcohol abuse, and caffeine
consumption may reveal the possible cause or causes of the infertility. Menstrual history and any medications being
taken, and a profile of the patient's general medical and emotional health can help in deciding on appropriate tests.
Also fasting measurements of plasma prolactin may be obtained to rule out hyperprolactinemia.

Diagnostic and Imaging Tests
1. Imaging tests for examining the uterus and fallopian tubes include ultrasound (particularly saline-infusion
sonohysterography), hysterosalpingography, hysteroscopy.

- 1.Centers for Disease Control and Prevention. Key statistics from the National Survey of Family Growth—I listing. Accessed April 28, 2020. https://www.cdc.gov/nchs/nsfg/key_statistics/i_2015-2017.htm#infertility
- 2.Ethics T, Medicine R; Ethics Committee of American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion. Fertil Steril. 2013;100(6):1524–1527. doi: 10.1016/j.fertnstert.2013.08.042 [DOI] [PubMed] [Google Scholar]
- 3.American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline: committee opinion No. 589. Fertil Steril. 2014;101(3):633–634. doi: 10.1016/j.fertnstert.2013.12.032 [DOI] [PubMed] [Google Scholar]
- 4.Infertility workup for the women's health specialist: ACOG committee opinion number 781. Obstet Gynecol. 2019;133(6):1294–1295. doi: 10.1097/AOG.0000000000003272 [DOI] [PubMed] [Google Scholar]

- 5.Gelbaya TA, Potdar N, Jeve YB, Nardo LG. Definition and epidemiology of unexplained infertility. Obstet Gynecol Surv. 2014;69(2):109–115. doi: 10.1097/OGX.0000000000000043 [DOI] [PubMed] [Google Scholar]
- 6.Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 1995;10(10):2705–2712. doi: 10.1093/oxfordjournals.humrep.a135772 [DOI] [PubMed] [Google Scholar]
- 7.Pfeifer S, Butts S, Dumesic D, et al. ; Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2015;103(3):e18–e25. doi: 10.1016/j.fertnstert.2014.12.103 [DOI] [PubMed] [Google Scholar]
- 8.Penzias A, Bendikson K, Falcone T, et al. ; Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril. 2020;113(2):305–322. doi: 10.1016/j.fertnstert.2019.10.014 [DOI] [PubMed] [Google Scholar]
- 9.Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44–e50. doi: 10.1016/j.fertnstert.2015.03.019 [DOI] [PubMed] [Google Scholar]
- 10.Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril. 2012; 98(3):591–598. doi: 10.1016/j.fertnstert.2012.05.031 [DOI] [PubMed] [Google Scholar]
- 11.Recent advances in medically assisted conception: report of a WHO scientific group. World Health Organ Tech Rep Ser. 1992;820(820):1–111. [PubMed] [Google Scholar]
- 12.Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13. doi: 10.2147/CLEP.S37559 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2015;104(5): 1116–1126. doi: 10.1016/j.fertnstert.2015.08.018 [DOI] [PubMed] [Google Scholar]
- 14.Boutari C, Pappas PD, Mintziori G, et al. The effect of underweight on female and male reproduction. Metabolism. 2020;107:154229. doi: 10.1016/j.metabol.2020.154229 [DOI] [PubMed] [Google Scholar]
- 15.Audu BM, Massa AA, Bukar M, El-Nafaty AU, Sa'ad ST. Prevalence of utero-tubal infertility. J Obstet Gynaecol. 2009;29(4):326–328. doi: 10.1080/01443610902803625 [DOI] [PubMed] [Google Scholar]

- 16.Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertil Steril. 2015;103(6):e37–e43. doi: 10.1016/j.fertnstert.2015.03.032 [DOI] [PubMed] [Google Scholar]
- 17.Broeze KA, Opmeer BC, Van Geloven N, et al. Are patient characteristics associated with the accuracy of hysterosalpingography in diagnosing tubal pathology? an individual patient data meta-analysis. Hum Reprod Update. 2011;17(3):293–300. doi: 10.1093/humupd/dmq056 [DOI] [PubMed] [Google Scholar]
- 18.Fang F, Bai Y, Zhang Y, Faramand A. Oil-based versus water-based contrast for hysterosalpingography in infertile women: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2018;110(1):153–160.e3. doi: 10.1016/j.fertnstert.2018.03.021 [DOI] [PubMed] [Google Scholar]
- 19.Dreyer K, van Rijswijk J, Mijatovic V, et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017;376(21):2043–2052. doi: 10.1056/NEJMoa1612337 [DOI] [PubMed] [Google Scholar]
- 20.Maheux-Lacroix S, Boutin A, Moore L, et al. Hysterosalpingosonography for diagnosing tubal occlusion in subfertile women: a systematic review with meta-analysis. Hum Reprod. 2014;29(5):953–963. doi: 10.1093/humrep/deu024 [DOI] [PubMed] [Google Scholar]
- 21.Tan J, Tannus S, Taskin O, Kan A, Albert AY, Bedaiwy MA. The effect of unilateral tubal block diagnosed by hysterosalpingogram on clinical pregnancy rate in intrauterine insemination cycles: systematic review and meta-analysis. BJOG. 2019; 126(2):227–235. doi: 10.1111/1471-0528.15457 [DOI] [PubMed] [Google Scholar]
- 22.Melo P, Georgiou EX, Johnson N, et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2020;10(10):CD002125. doi: 10.1002/14651858.CD002125.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ozkan S, Murk W, Arici A. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci. 2008;1127:92–100. doi: 10.1196/annals.1434.007 [DOI] [PubMed] [Google Scholar]
- 24.Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril. 2012; 98(3):591–598. doi: 10.1016/j.fertnstert.2012.05.031 [DOI] [PubMed] [Google Scholar]
- 25.Lessey BA, Young SL. What exactly is endometrial receptivity? Fertil Steril. 2019;111(4): 611–617. doi: 10.1016/j.fertnstert.2019.02.009 [DOI] [PubMed] [Google Scholar]

- 26.Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;2014(3):CD009590. doi: 10.1002/14651858.CD009590.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Schwartz D, Mayaux MJ; Federation CECOS. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. N Engl J Med. 1982; 306(7):404–406. doi: 10.1056/NEJM198202183060706 [DOI] [PubMed] [Google Scholar]
- 28.Venetis CA, Papadopoulos SP, Campo R, Gordts S, Tarlatzis BC, Grimbizis GF. Clinical implications of congenital uterine anomalies: a meta-analysis of comparative studies. Reprod Biomed Online. 2014; 29(6):665–683. doi: 10.1016/j.rbmo.2014.09.006 [DOI] [PubMed] [Google Scholar]
- 29.Bittencourt CA, Dos Santos Simões R, Bernardo WM, et al. Accuracy of saline contrast sonohysterography in detection of endometrial polyps and submucosal leiomyomas in women of reproductive age with abnormal uterine bleeding: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017;50(1):32–39. doi: 10.1002/uog.17352 [DOI] [PubMed] [Google Scholar]
- 30.Bosteels J, van Wessel S, Weyers S, et al. Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev. 2018;12:CD009461. doi: 10.1002/14651858.CD009461.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bernardi LA, Carnethon MR, de Chavez PJ, et al. Relationship between obesity and anti-Müllerian hormone in reproductive-aged African American women. Obesity (Silver Spring). 2017;25(1):229–235. doi: 10.1002/oby.21681 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Moy V, Jindal S, Lieman H, Buyuk E. Obesity adversely affects serum anti-müllerian hormone (AMH) levels in Caucasian women. J Assist Reprod Genet. 2015;32(9):1305–1311. doi: 10.1007/s10815-015-0538-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–130. doi: 10.1093/humupd/dmp036 [DOI] [PubMed] [Google Scholar]
- 34.Tal R, Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol. 2017;217(2): 129–140. doi: 10.1016/j.ajog.2017.02.027 [DOI] [PubMed] [Google Scholar]

- 35.Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum Reprod. 2002;17(1):118–123. doi: 10.1093/humrep/17.1.118 [DOI] [PubMed] [Google Scholar]
- 36.ACOG committee opinion No. 773: the use of antimüllerian hormone in women not seeking fertility care. Obstet Gynecol. 2019;133(4):e274–e278. doi: 10.1097/AOG.0000000000003162 [DOI] [PubMed] [Google Scholar]
- 37.Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77(3):468–471. doi: 10.1016/S0015-0282(01)03201-0 [DOI] [PubMed] [Google Scholar]
- 38.Chan YY, Jayaprakasan K, Tan A, Thornton JG, Coomarasamy A, Raine-Fenning NJ. Reproductive outcomes in women with congenital uterine anomalies: a systematic review. Ultrasound Obstet Gynecol. 2011;38(4):371–382. doi: 10.1002/uog.10056 [DOI] [PubMed] [Google Scholar]
- 39.Fujimoto VY, Miller JH, Klein NA, Soules MR. Congenital cervical atresia: report of seven cases and review of the literature. Am J Obstet Gynecol. 1997;177(6):1419–1425. doi: 10.1016/S0002-9378(97)70085-1 [DOI] [PubMed] [Google Scholar]
- 40.Martyn F, McAuliffe FM, Wingfield M. The role of the cervix in fertility: is it time for a reappraisal? Hum Reprod. 2014;29(10):2092–2098. doi: 10.1093/humrep/deu195 [DOI] [PubMed] [Google Scholar]
- 41.Odisho AY, Nangia AK, Katz PP, Smith JF. Temporal and geospatial trends in male factor infertility with assisted reproductive technology in the United States from 1999–2010. Fertil Steril. 2014;102(2):469–475. doi: 10.1016/j.fertnstert.2014.05.006 [DOI] [PubMed] [Google Scholar]
- 42.Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Oehninger S. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril. 1988;49(1):112–117. doi: 10.1016/S0015-0282(16)59660-5 [DOI] [PubMed] [Google Scholar]
- 43.van der Steeg JW, Steures P, Eijkemans MJC, et al. ; Collaborative Effort for Clinical Evaluation in Reproductive Medicine Study Group. Role of semen analysis in subfertile couples. Fertil Steril. 2011;95 (3):1013–1019. doi: 10.1016/j.fertnstert.2010.02.024 [DOI] [PubMed] [Google Scholar]
- 44.Practice T, Medicine R; Practice Committee of the American Society for Reproductive Medicine. Management of nonobstructive azoospermia: a committee opinion. Fertil Steril. 2018;110(7):1239–1245. doi: 10.1016/j.fertnstert.2018.09.012 [DOI] [PubMed] [Google Scholar]

- 45.Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action: a hypothesis revisited. Fertil Steril. 1984;42(3):331–344. doi: 10.1016/S0015-0282(16)48069-6 [DOI] [PubMed] [Google Scholar]
- 46.Legro RS, Brzyski RG, Diamond MP, et al. ; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129. doi: 10.1056/NEJMoa1313517 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;5(5):CD010287. doi: 10.1002/14651858.CD010287.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Christou F, Pitteloud N, Gomez F. The induction of ovulation by pulsatile administration of GnRH: an appropriate method in hypothalamic amenorrhea. Gynecol Endocrinol. 2017;33(8):598–601. doi: 10.1080/09513590.2017.1296948 [DOI] [PubMed] [Google Scholar]
- 49.Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril. 1997;67(2):256–260. doi: 10.1016/S0015-0282(97)81907-3 [DOI] [PubMed] [Google Scholar]
- 50.Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305–309. doi: 10.1016/S0015-0282(00)01705-2 [DOI] [PubMed] [Google Scholar]
- 51.Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. 2016;106(7):1634–1647. doi: 10.1016/j.fertnstert.2016.08.048 [DOI] [PubMed] [Google Scholar]
- 52.Practice Committees of the American Society for Reproductive Medicine and Society for Reproductive Endocrinology and Infertility. Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion. Fertil Steril. 2020;113(1):66–70. doi: 10.1016/j.fertnstert.2019.09.020 [DOI] [PubMed] [Google Scholar]
- 53.Homburg R, Eshel A, Armar NA, et al. One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulation. BMJ. 1989;298(6676):809–812. doi: 10.1136/bmj.298.6676.809 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 54.Hurley DM, Brian R, Outch K, et al. Induction of ovulation and fertility in amenorrheic women by pulsatile low-dose gonadotropin-releasing hormone. N Engl J Med. 1984;310(17):1069–1074. doi: 10.1056/NEJM198404263101702 [DOI] [PubMed] [Google Scholar]

- 55.Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF; Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904–909. doi: 10.1056/NEJM199410063311403 [DOI] [PubMed] [Google Scholar]

- 56.Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;1(1): CD010290. doi: 10.1002/14651858.CD010290.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 57.Cissen M, Bensdorp A, Cohlen BJ, Repping S, de Bruin JP, van Wely M. Assisted reproductive technologies for male subfertility. Cochrane Database Syst Rev. 2016;2(2):CD000360. doi: 10.1002/14651858.CD000360 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 58.Bhattacharya S, Harrild K, Mollison J, et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ. 2008;337:a716. doi: 10.1136/bmj.a716 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 59.Scott RT Jr, Upham KM, Forman EJ, et al. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertil Steril. 2013;100(3):697–703. doi: 10.1016/j.fertnstert.2013.04.035 [DOI] [PubMed] [Google Scholar]

- 60.Rubio C, Bellver J, Rodrigo L, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017; 107(5):1122–1129. doi: 10.1016/j.fertnstert.2017.03.011 [DOI] [PubMed] [Google Scholar]

- 61.Penzias A, Bendikson K, Butts S, et al. ; Practice Committees of the American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. Fertil Steril. 2018;109 (3):429–436. doi: 10.1016/j.fertnstert.2018.01.002 [DOI] [PubMed] [Google Scholar]

- 62.Victor AR, Tyndall JC, Brake AJ, et al. One hundred mosaic embryos transferred prospectively in a single clinic: exploring when and why they result in healthy pregnancies. Fertil Steril. 2019;111 (2):280–293. doi: 10.1016/j.fertnstert.2018.10.019 [DOI] [PubMed] [Google Scholar]

- 63.Fragouli E, Alfarawati S, Spath K, et al. Analysis of implantation and ongoing pregnancy rates following the transfer of mosaic diploid-aneuploid blastocysts. Hum Genet. 2017;136(7):805–819. doi: 10.1007/s00439-017-1797-4 [DOI] [PubMed] [Google Scholar]

- 64.Brännström M, Johannesson L, Bokström H, et al. Livebirth after uterus transplantation. Lancet. 2015;385(9968):607–616. doi: 10.1016/S0140-6736(14)61728-1 [DOI] [PubMed] [Google Scholar]

- 65.Ejzenberg D, Andraus W, Baratelli Carelli Mendes LR, et al. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility. Lancet. 2019;392 (10165):2697–2704. doi: 10.1016/S0140-6736(18)31766-5 [DOI] [PubMed] [Google Scholar]

- 66.Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the Fast Track and Standard Treatment (FASTT) trial. Fertil Steril. 2010;94(3):888–899. doi: 10.1016/j.fertnstert.2009.04.022 [DOI] [PubMed] [Google Scholar]

- 67.Dovey S, Sneeringer RM, Penzias AS. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril. 2008;90(6):2281–2286. doi: 10.1016/j.fertnstert.2007.10.057 [DOI] [PubMed] [Google Scholar]

- 68.Centers for Disease Control and Prevention. 2017 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Centers for Disease Control and Prevention; 2017. [Google Scholar]

- 69.Goldman MB, Thornton KL, Ryley D, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). Fertil Steril. 2014;101(6):1574–81.e1, 2. doi: 10.1016/j.fertnstert.2014.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 70.Sermondade N, Huberlant S, Bourhis-Lefebvre V, et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4): 439–451. doi: 10.1093/humupd/dmz011 [DOI] [PubMed] [Google Scholar]

- 71.Legro RS, Dodson WC, Kunselman AR, et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin

Endocrinol Metab. 2016;101(7):2658–2666. doi: 10.1210/jc.2016-1659 [DOI] [PMC free article] [PubMed] [Google Scholar]

- 72.Einarsson S, Bergh C, Friberg B, et al. Weight reduction intervention for obese infertile women prior to IVF: a randomized controlled trial. Hum Reprod. 2017;32(8):1621–1630. doi: 10.1093/humrep/dex235 [DOI] [PubMed] [Google Scholar]
- 73.Kluge L, Bergh C, Einarsson S, Pinborg A, Mikkelsen Englund A-L, Thurin-Kjellberg A. Cumulative live birth rates after weight reduction in obese women scheduled for IVF: follow-up of a randomized controlled trial. Hum Reprod Open. 2019;2019(4):hoz030. doi: 10.1093/hropen/hoz030 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Reynolds KA, Boudoures AL, Chi MM, Wang Q, Moley KH. Adverse effects of obesity and/or high-fat diet on oocyte quality and metabolism are not reversible with resumption of regular diet in mice. Reprod Fertil Dev. 2015;27(4):716–724. doi: 10.1071/RD14251 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Legro RS, Barnhart HX, Schlaff WD, et al. ; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–566. doi: 10.1056/NEJMoa063971 [DOI] [PubMed] [Google Scholar]
- 76.Gaskins AJ, Nassan FL, Chiu YH, et al. ; EARTH Study Team. Dietary patterns and outcomes of assisted reproduction. Am J Obstet Gynecol. 2019; 220(6):567.e1–567.e18. doi: 10.1016/j.ajog.2019.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Salas-Huetos A, Bulló M, Salas-Salvadó J. Dietary patterns, foods and nutrients in male fertility parameters and fecundability: a systematic review of observational studies. Hum Reprod Update. 2017;23(4):371–389. doi: 10.1093/humupd/dmx006 [DOI] [PubMed] [Google Scholar]
- 78.Pfeifer S, Butts S, Fossum G, et al. ; Practice Committee of the American Society for Reproductive Medicine; Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility: a committee opinion. Fertil Steril. 2017;107(1):52–58. doi: 10.1016/j.fertnstert.2016.09.029 [DOI] [PubMed] [Google Scholar]
- 79.Wen J, Jiang J, Ding C, et al. Birth defects in children conceived by in vitro fertilization and intracytoplasmic sperm injection: a meta-analysis. Fertil Steril. 2012;97(6):1331–1337. doi: 10.1016/j.fertnstert.2012.02.053 [DOI] [PubMed] [Google Scholar]
- 80.Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012;366(19):1803–1813. doi: 10.1056/NEJMoa1008095 [DOI] [PubMed] [Google Scholar]

- 81.Sharma S, Ghosh S, Singh S, et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One. 2014;9(10):e108219. doi: 10.1371/journal.pone.0108219 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85(6):1761–1765. doi: 10.1016/j.fertnstert.2006.03.014 [DOI] [PubMed] [Google Scholar]
- 83.Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can. 2007;29(8):668–671. doi: 10.1016/S1701-2163(16)32551-8 [DOI] [PubMed] [Google Scholar]
- 84.Akbari Sene A, Ghorbani S, Ashrafi M. Comparison of the pregnancy outcomes and the incidence of fetal congenital abnormalities in infertile women treated with letrozole and clomiphene citrate. J Obstet Gynaecol Res. 2018;44(6):1036–1041. doi: 10.1111/jog.13644 [DOI] [PubMed] [Google Scholar]
- 85.Qin J, Wang H, Sheng X, Liang D, Tan H, Xia J. Pregnancy-related complications and adverse pregnancy outcomes in multiple pregnancies resulting from assisted reproductive technology: a meta-analysis of cohort studies. Fertil Steril. 2015;103(6):1492–508.e1, 7. doi: 10.1016/j.fertnstert.2015.03.018 [DOI] [PubMed] [Google Scholar]
- 86.Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 2019;6:CD008215. doi: 10.1002/14651858.CD008215.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Skalkidou A, Sergentanis TN, Gialamas SP, et al. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. Cochrane Database Syst Rev. 2017;3(3):CD010931. doi: 10.1002/14651858.CD010931.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Pfeifer S, Butts S, Dumesic D, et al. ; Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril. 2016;106(7):1617–1626. doi: 10.1016/j.fertnstert.2016.08.035 [DOI] [PubMed] [Google Scholar]
- 89.Eisenberg ML, Li S, Brooks JD, Cullen MR, Baker LC. Increased risk of cancer in infertile men: analysis of US claims data. J Urol. 2015;193(5):1596–1601. doi: 10.1016/j.juro.2014.11.080 [DOI] [PubMed] [Google Scholar]

- 90.Legro RS, Arslanian SA, Ehrmann DA, et al. ; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.ACOG committee opinion number 605: primary ovarian insufficiency in adolescents and young women. Obstetrics. 2002;99(4):679–680. doi: 10.1016/S0029-7844(02)01986-5 [DOI] [PubMed] [Google Scholar]
- 92.Gleason JL, Shenassa ED, Thoma ME. Self-reported infertility, metabolic dysfunction, and cardiovascular events: a cross-sectional analysis among US women. Fertil Steril. 2019;111(1):138–146. doi: 10.1016/j.fertnstert.2018.10.009 [DOI] [PubMed] [Google Scholar]
- 93.Stentz NC, Koelper N, Barnhart KT, Sammel MD, Senapati S. Infertility and mortality. Am J Obstet Gynecol. 2020;222(3):251.e1–251.e10. doi: 10.1016/j.ajog.2019.09.007 [DOI] [PubMed] [Google Scholar]
- 94.Salonia A, Matloob R, Gallina A, et al. Are infertile men less healthy than fertile men? results of a prospective case-control survey. Eur Urol. 2009;56(6):1025–1031. doi: 10.1016/j.eururo.2009.03.001 [DOI] [PubMed] [Google Scholar]
- 95.Glazer CH, Bonde JP, Giwercman A, et al. Risk of diabetes according to male factor infertility: a register-based cohort study. Hum Reprod. 2017;32(7):1474–1481. doi: 10.1093/humrep/dex097 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Fakih MH, El Shmoury M, Szeptycki J, et al. The AUGMENT treatment: physician reported outcomes of the initial global patient experience. J Fertil. 2015;03(03). doi: 10.4172/2375-4508.1000154 [DOI] [Google Scholar]
- 97.Oktay K, Baltaci V, Sonmezer M, et al. Oogonial precursor cell-derived autologous mitochondria injection to improve outcomes in women with multiple IVF failures due to low oocyte quality: a clinical translation. Reprod Sci. 2015;22(12):1612–1617. doi: 10.1177/1933719115612137 [DOI] [PubMed] [Google Scholar]
- 98.Labarta E, de Los Santos MJ, Herraiz S, et al. Autologous mitochondrial transfer as a complementary technique to intracytoplasmic sperm injection to improve embryo quality in patients undergoing in vitro fertilization: a randomized pilot study. Fertil Steril. 2019;111(1): 86–96. doi: 10.1016/j.fertnstert.2018.09.023 [DOIPubMedGoogle Scholar